Arrowhead Pharmaceuticals Inc (ARWR)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Arrowhead Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 15 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 86.00 $ — 96% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
2/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 158.7%
- Exp. sales growth 3Y > 5% -37.8%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -37.8%
- Net debt < 4x EBIT -5.6x
- EBIT positive, 10Y straight 2
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -0.4%
- ROCE > 15% 8.3%
- Expected return > 10% -37.0%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
7 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 50.5% passed
- More than 10% revenue growth is expected for the coming year -24.1% failed
- Share count grows by less than 3% a year 8.3% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 23,277.1% passed
- Gross margin at 40% or higher and without meaningful erosion 100.0% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 553 m net cash passed
- Operating cash flow covers the profits of the last three years 369 m passed
- Return on capital at 15% or higher, or up versus two years ago 8.3% passed
- Insiders hold at least 10% or are net buyers 3.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 25.7% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 13
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 09/30/2026 | -3.11 | -3.82 – -1.85 | 439 | -31,004.3% | 11 |
| 09/30/2027 | -4.60 | -6.70 – -2.02 | 321 | -48.0% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -1.19 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.39 | – | 3 | -29.60 | -6,923.40 | -146 | -154 |
| 2025: Q1 | 2.75 | – | 543 | – | 68.30 | 460 | 455 |
| 2025: Q2 | -1.26 | – | 28 | – | -631.10 | -155 | -157 |
| 2025: Q3 | -0.18 | – | 257 | 987.30 | -9.30 | 21 | 13 |
| 2025: Q4 | 0.22 | – | 264 | 10,461.30 | 11.70 | 14 | 11 |
| 2026: Q1 | -0.93 | -133.80 | 74 | -86.40 | -180.00 | 84 | 82 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -82 | -82 | -1.34 | -64 | 96 | 128 |
| 2017 | 31 | -37 | -34 | -0.47 | -24 | 81 | 104 |
| 2018 | 16 | -56 | -54 | -0.65 | -47 | 96 | 112 |
| 2019 | 169 | 61 | 68 | 0.69 | 173 | 245 | 350 |
| 2020 | 88 | -93 | -85 | -0.84 | -96 | 462 | 523 |
| 2021 | 138 | -149 | -141 | -1.36 | 171 | 409 | 710 |
| 2022 | 243 | -179 | -176 | -1.67 | -136 | 399 | 692 |
| 2023 | 241 | -205 | -205 | -1.92 | -154 | 271 | 766 |
| 2024 | 4 | -601 | -599 | -5.00 | -463 | 185 | 1,140 |
| 2025 | 829 | 98 | -2 | -0.01 | 180 | 466 | 1,385 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Arrowhead Pharmaceuticals, Inc. entwickelt Medikamente zur Behandlung schwer behandelbarer Erkrankungen in den USA.
| Employees | 711 |
|---|---|
| Headquarters | Pasadena, CA |
| Address | 177 East Colorado Boulevard, 91105 Pasadena, United States |
| Phone | 626 304 3400 |
| Website | arrowheadpharma.com |
| IPO Date | 16. Jun 1993 |
| ISIN | US04280A1007 |
| Stock Split | 1:10 on 11/17/2011 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Christopher R. Anzalone Ph.D. | Chairman, CEO & President | 1969 |
| Daniel J. Apel | Chief Financial Officer | 1966 |
| Patrick O'Brien J.D., PharmD | COO & Secretary | 1964 |
| James C. Hamilton M.D., MBA | Chief Medical Officer and Head of R&D | 1979 |
| Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando | – |
| Tao Pei Ph.D. | Chief Scientific Officer | – |
| Vincent Anzalone CFA | Head of Investor Relations & VP | – |
| Howard Lovy | Director of Communications | – |
| Bruce D. Given M.D. | Chief Medical Scientist | 1954 |
| Mark Seefeld | Head of Toxicology & VP | 1954 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 23. Apr 2026 | James C Hamilton | Insider | Sell | 10,000 | 75.00 | 750,000 |
| 22. Apr 2026 | Daniel Joseph Apel | CFO | Sell | 13,095 | 71.35 | 934,328 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.